- Home
- VHUB vs KLRS Comparison
VHUB vs KLRS Comparison
Compare VHUB & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VHUB | KLRS |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.6M | 92.8M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VHUB | KLRS |
|---|---|---|
| Price | $0.42 | $2.49 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $18.71 |
| AVG Volume (30 Days) | ★ 259.7K | 61.1K |
| Earning Date | 11-14-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.70 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $864,450.00 | $165,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.38 | $2.35 |
| 52 Week High | $15.34 | $11.88 |
Technical Indicators
Market Signals| Indicator | VHUB | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 32.37 | 17.64 |
| Support Level | N/A | N/A |
| Resistance Level | $0.80 | $4.37 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 10.91 | 11.58 |
Price Performance
Historical ComparisonAbout VHUB VenHub Global Inc. Common Stock
Venhub Global Inc is engaged in designing and building autonomous Smart Stores that operate 24/7 without on-site staff. Each store combines robotic automation, real-time inventory tracking, and mobile-based checkout to provide secure, convenient retail access, and is offered as an integrated retail solution to store operators.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.